The recommended minimum dose is 1.36 mg/lb (3 mg/kg) emodepside + 5.45 mg/lb (12 mg/kg) praziquantel as a single topical dose. A single treatment is effective and a second treatment should not be necessary. If re-infection occurs, the product can be re-applied after 30 days. 1. Select the package that correctly corresponds with the body weight of the cat. (See Table below.) * Cats over 17.6 lbs should be treated w...
Storage and handling
Store at or below 77º F (25º C). Protect from freezing.
CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.
Topical Solution for the treatment and control of hookworm, roundworm and tapeworm infections in cats and kittens that are at least 8 weeks of age and weigh at least 2.2 lbs (1 kg).
DESCRIPTION:
DESCRIPTION SECTION
PROFENDER [1.98% emodepside/7.94% praziquantel] Topical Solution is a clear yellow ready-to-use solution packaged in single unit dosing applicator tubes for topical (dermal) treatment of cats 8 weeks of age and older and weighing at least 2.2 lbs (1 kg). The formulation and dosage schedule is designed to provide a minimum of 1.36 mg/lb (3 mg/kg) emodepside and 5.45 mg/lb (12 mg/kg) praziquantel based on body weight. Emodepside, a semi-synthetic molecule, is a cyclic depsipeptide. The chemical name is Cyclo [D-2-hydroxypropanoyl-N-methyl-L-leucyl-3-[4-(4-morpholinyl)phenyl]-D-2-hydroxypropanoyl-N-methyl-L-leucyl-D-2-hydroxypropanoyl-N-methyl-L-leucyl-3-[4-(4-morpholinyl)phenyl]-D-2-hydroxypropanoyl-N-methyl-L-leucyl]. Praziquantel is an isoquinoline cestocide. The chemical name is 2-Cyclohexylcarbonyl-1,2,3,6,7,11b-hexahydro-4H-pyrazine-2,1-a-iso-quinoline-4-one.
INDICATIONS:
INDICATIONS & USAGE SECTION
PROFENDER Topical Solution is indicated for the treatment and control of hookworm infections caused by Ancylostoma tubaeforme (adults, immature adults, and fourth stage larvae), roundworm infections caused by Toxocara cati (adults and fourth stage larvae), and tapeworm infections caused by Dipylidium caninum (adults) and Taenia taeniaeformis (adults) in cats.
DOSAGE AND ADMINISTRATION:
DOSAGE & ADMINISTRATION SECTION
The recommended minimum dose is 1.36 mg/lb (3 mg/kg) emodepside + 5.45 mg/lb (12 mg/kg) praziquantel as a single topical dose. A single treatment is effective and a second treatment should not be necessary. If re-infection occurs, the product can be re-applied after 30 days.
1.Select the package that correctly corresponds with the body weight of the cat. (See Table below.)
* Cats over 17.6 lbs should be treated with the appropriate combination of tubes.
Cat Weight*
Profender Topical Solution
Volume (mL)
Emodepside (mg)
Praziquantel (mg)
2.2-5.5 lbs.
Small
0.35
7.5
30.0
>5.5-11 lbs.
Medium
0.70
15.0
60.1
>11-17.6 lbs.
Large
1.12
24.0
96.1
2.Remove one unit dose tube from the package.
3.While holding the tube in an upright position, remove the cap from the tube.
4.Turn the cap over and place the other end of cap onto the tip of the tube.
5.Twist the cap to break the seal and then remove cap from the tube.
Figure 1
6.Part the hair on the back of the cat’s neck at the base of the head, until the skin is visible.
Figure 2
7.The ensure the entire contents of the tube are administered, place the tip of the tube on the skin and squeeze the entire contents directly onto the skin. Lift tube away from the skin before releasing pressure on the tube.
Do not apply to broken skin or if hair coat is wet. Do not get this product in the cat’s mouth or eyes or allow the cat to lick the application site for one hour. Oral exposure can cause salivation and vomiting. Treatment at the base of the head will minimize the opportunity for ingestion while grooming. In households with multiple pets, keep animals separated to prevent licking of the application site.
Stiff hair, a damp appearance of the hair, or a slight powdery residue may be observed at the treatment site. These effects are temporary and do not affect the safety or effectiveness of the product.
HUMAN WARNINGS:
WARNINGS SECTION
Not for human use. Keep out of reach of children.
To prevent accidental ingestion of the product, children should not come in contact with the application site for twenty-four (24) hours while the product is being absorbed. Pregnant women, or women who may become pregnant, should avoid direct contact with, or wear disposable gloves when applying, this product. Studies performed in rats and rabbits suggest that emodepside may interfere with fetal development in those species.
PROFENDER Topical Solution may be irritating to skin and eyes. Reactions such as facial, tongue and hand swelling have been reported in humans in rare instances. Avoid contact with the application area while it is wet and wash hands thoroughly with soap and warm water after handling. People with known hypersensitivity to butylhydroxyanisole, emodepside or praziquantel should administer the product with caution. If the product accidentally gets into eyes, flush thoroughly with water. May be harmful if swallowed. In case of accidental ingestion or if skin or eye irritation occurs, call a poison control center or physician for treatment advice.
The Safety Data Sheet (SDS) provides additional occupational safety information. For product questions, to report adverse reactions, or for a copy of the Safety Data Sheet (SDS), call Elanco Product & Veterinary Support at 888-545-5973.
PRECAUTIONS:
PRECAUTIONS SECTION
Safe use of this product has not been evaluated in cats less than 8 weeks of age or weighing less than 2.2 lbs (1 kg), in cats used for breeding, during pregnancy or in lactating queens. The effectiveness of this product when used before bathing has not been evaluated.
Use with caution in sick or debilitated cats. Oral ingestion or exposure should be avoided. Use with caution in heartworm positive cats. The cats enrolled in the field study were heartworm antigen and antibody negative prior to entering the study. In a laboratory study, cats artificially infected with adult heartworms and treated with PROFENDER Topical Solution had fewer worms recovered than the placebo control group. (See ANIMAL SAFETY.)
ADVERSE REACTIONS:
ADVERSE REACTIONS SECTION
Field study: In a controlled, double-masked field safety study, owners administered PROFENDER Topical Solution to 606 cats. Adverse reactions reported by the cat owners included licking/excessive grooming in 18 cats (3.0%), scratching treatment site in 15 cats (2.5%), salivation in 10 cats (1.7%), lethargy in 10 cats (1.7%), alopecia in 8 cats (1.3%), agitation/nervousness in 7 cats (1.2%), vomiting in 6 cats (1.0%), diarrhea in 3 cats (0.5%), eye irritation in 3 cats (0.5%), respiratory irritation in 1 cat (0.2%) and shaking/tremors in 1 cat (0.2%). All adverse reactions were self-limiting.
Laboratory effectiveness studies: One cat died 10 days after receiving PROFENDER Topical Solution. The necropsy showed chronic active cholangiohepatitis. While the use of the drug did not appear to be the direct cause of death, treatment with the drug cannot be ruled out as a contributing factor (See PRECAUTIONS). One cat treated with a vehicle placebo (formulation minus the active ingredients) showed salivation, gagging, lethargy and a swollen tongue.
Foreign Market Experience: The following adverse events were reported voluntarily during post-approval use of the product in foreign markets: application site reaction (hair loss, dermatitis, pyoderma, edema, and erythema), salivation, pruritus, lethargy, vomiting, diarrhea, dehydration, ataxia, loss of appetite, facial swelling, rear leg paresis, seizures, hyperesthesia, twitching, and death.
Post-Approval Experience: The following adverse events are based on post-approval adverse drug experience reporting. Not all adverse events are reported to FDA CVM. It is not always possible to reliably estimate the adverse event frequency or establish a causal relationship to product exposure using this data. The following adverse events are listed in decreasing order of reporting frequency in cats: Application site reaction (hair loss, dermatitis, pyoderma, edema, and erythema), hypersalivation, lethargy/depression, vomiting, ataxia, anorexia, trembling/twitching, diarrhea, mydriasis, fever, hyper-activity/nervousness. In some cases, death has been reported as an outcome of the adverse events listed. For a complete listing of the adverse reactions for Profender Topical Solution reported to the CVM see: www.fda.gov/ADEreports.
This listing includes Adverse Events reported to CVM for products, such as Profender, that contain the combined active ingredients emodepside and praziquantel. Listings by active ingredient may represent more than one brand name.
CONTACT INFORMATION:
For product questions, to report adverse reactions, or for a copy of the Safety Data Sheet (SDS), call Elanco Product & Veterinary Support at 888-545-5973. For additional information about reporting adverse drug experiences for animal drugs, contact FDA at 1-888-FDA-VETS or www.fda.gov/reportanimalae.
EFFECTIVENESS:
SUMMARY OF SAFETY AND EFFECTIVENESS
In a total of 13 controlled laboratory studies to establish effectiveness, 149 cats were treated with PROFENDER Topical Solution. In the field study conducted at 13 veterinary clinics/hospitals, 837 purebred or crossbred cats from single and multi-cat households were enrolled to evaluate safety and effectiveness under field conditions of use. Of those, 606 received a single treatment with PROFENDER Topical Solution. Cats ranged in age between 2 months and 17 years and weighed between 0.8 lbs (0.36 kg) and 21 lbs (9.62 kg). Data from these studies demonstrated PROFENDER Topical Solution is safe and effective for the treatment and control of hookworm infections caused by Ancylostoma tubaeforme (adults, immature adults, and fourth stage larvae), roundworm infections caused by Toxocara cati (adults and fourth stage larvae), and tapeworm infections caused by Dipylidium caninum (adults) and Taenia taeniaeformis (adults).
ANIMAL SAFETY:
OTHER SAFETY INFORMATION
In a field study, PROFENDER Topical Solution was used in cats receiving other frequently used products including: analgesics, anti-fungals, non-steroidal anti-inflammatories, anthelmintics, antimicrobials, flea and tick products, sedatives, anesthetics, cardiac medications, anxiolytics, hormonal treatments, steroids, otic and ophthalmic preparations, and vaccines.
SPL UNCLASSIFIED SECTION
Dose Tolerance Study in Cats: PROFENDER Topical Solution was applied topically one time to young cats at 10X the recommended label use rate. Two cats salivated. Another cat exhibited tremors and lethargy. These signs were self-limiting.
SPL UNCLASSIFIED SECTION
Oral Safety Studies in Cats: PROFENDER Topical Solution was administered orally at the recommended topical dose to young adult cats. The cats exhibited salivation, vomiting, tremors, abnormal gait, abnormal respiration and weight loss. These signs were self-limiting.
SPL UNCLASSIFIED SECTION
General Safety Study in Kittens: PROFENDER Topical Solution was topically applied at 0X (vehicle control), 1X, 3X and 5X the maximum dose to 48 healthy 8-week-old kittens every two weeks for six doses. One 5X kitten experienced salivation and tremors and another 5X kitten experienced salivation on the day of dosing. A third 5X kitten experienced tremors the day after dosing. Three cats vomited within 24 hours of dosing, one each in vehicle control, 3X and 5X groups.
SPL UNCLASSIFIED SECTION
Safety Study in Heartworm Positive Cats: Cats artificially infected with adult heartworms harvested from dogs were treated topically with PROFENDER Topical Solution at 0X, 1X or 5X the recommended dose once a month for three treatments. Clinical signs included salivation (one 1X and three 5X cats), labored breathing (all groups) and lethargy (one 5X cat). At the study conclusion, the 1X and 5X cats had fewer live heartworms recovered than the 0X group.
STORAGE INFORMATION:
STORAGE AND HANDLING SECTION
Store at or below 77º F (25º C).
Protect from freezing.
HOW SUPPLIED:
HOW SUPPLIED SECTION
Applications per Package
8 - 0.35 mL tubes (2 blisters of 4 tubes)
bracket
Variety Pack
20 - 0.7 mL tubes (5 blisters of 4 tubes)
8 - 1.12 mL tubes (2 blisters of 4 tubes)
20 - 0.35 mL tubes (5 blisters of 4 tubes)
40 - 0.35 mL tubes (10 blisters of 4 tubes)
20 - 0.7 mL tubes (5 blisters of 4 tubes)
40 - 0.7 mL tubes (10 blisters of 4 tubes)
20 - 1.12 mL tubes (5 blisters of 4 tubes)
40 - 1.12 mL tubes (10 blisters of 4 tubes)
Product of Germany
Approved by FDA under NADA # 141-275
Manufactured for: Elanco US Inc. Indianapolis, IN 46221 U.S.A
Do not dispense dose applicator without complete safety and administration information.
Indicated for the treatment and control of hookworm infections caused by Ancylostoma tubaeforme (adults, immature adult and fourth stage larvae), roundworm infections caused by Toxocara cati (adults and fourth stage larvae), and tapeworm infections caused by Dipylidium caninum (adults) and Taenia taeniaeformis (adults) in cats.
HUMAN WARNINGS: Not for human use. Keep out of reach of children. To prevent accidental ingestion of the product, children should not come into contact with the application site for twenty-four (24) hours while the product is being absorbed.
See package insert for complete product information.
CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Topical Solution for the treatment and control of hookworm, roundworm and tapeworm infections.
8 tubes
Small
For Cats and Kittens
8 weeks of age and older and weighing > 2.2-5.5 lbs
Contains 8 - 0.35 ml tubes
Each tube contains 7.5 mg of emodepside and 30 mg of praziquantel.
20 tubes
Medium
For Cats and Kittens
8 weeks of age and older and weighing > 5.5-11 lbs
Contains 20 - 0.70 ml tubes
Each tube contains 15 mg of emodepside and 60.1 mg of praziquantel.
8 tubes
Large
For Cats and Kittens
8 weeks of age and older and weighing > 11-17.6 lbs
Contains 8 - 1.12 ml tubes
Each tube contains 24 mg of emodepside and 96.1 mg of praziquantel.
See package insert for complete product information.
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.